Fig. 3From: Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behaviorEffect of HAp on coagulation: APTT, PT and Plasma recalcification time (1–10 mg/mL HAp). Both particles had minimal effects on blood compatibility assays, but HAp2 revealed a trend for decreased values at 10 mg/mL. *Significantly different from negative control; p ≤ 0.05Back to article page